ClinicalTrials.gg
CompletedNCT03337126Updated Jan 11, 2019

Bioavailability of ATI-1501 With Taste Test Sub Study

A Phase 1 interventional study of Metronidazole Tablet in Bioequivalence, sponsored by Appili Therapeutics Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.

Sponsored by Appili Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2017, 8 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Appili Therapeutics Inc. is developing an oral suspension formulation of metronidazole (ATI-1501), a taste-masked reformulation of metronidazole. The purpose of this study is to compare the relative bioavailability of ATI-1501 with the Reference Listed Drug (RLD) in healthy, adult volunteers to determine that it is Bioequivalent.

Read the detailed description

This is a Phase 1, single-center, randomized, open-label, single dose, 2 sequence, 2 treatment, crossover, relative bioavailability study of ATI-1501 under fasting and fed conditions in healthy adult subjects. The purpose of this study is to determine the relative bioavailability of ATI-1501 oral suspension to the comparator drug, Flagyl®. The study also aims to evaluate the safety and characterize the PK profile of ATI-1501 oral suspension in healthy adults. The PK of ATI-1501 oral suspension in a population of subjects with no concomitant illnesses will be recorded and analyzed. Blood samples will be collected through individual venipuncture or an indwelling catheter at pre-described time intervals throughout the study to determine the bioavailability of ATI-1501 oral suspension and characterize its overall PK profile. In addition, blood samples will also be collected using a microsampling device to validate the use of blood microsampling for future studies. Subjects will be randomized to 1 of 2 treatment sequences and each group of subjects will undergo 4 periods of treatment. Each subject will receive each treatment regimen in this crossover study design, allowing for a 7-day washout period. The study drugs will be administered under fasting and fed conditions to evaluate the effects of food on the absorption of metronidazole, administered in the ATI-1501 oral suspension. The palatability of ATI-1501 will be assessed using the 9-point scale to assess the taste, texture, and smell of the 2 study drugs. A 3-point scale will be used to evaluate the degree of bitterness of the 2 study drugs

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Appili Therapeutics Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects 18 to 65 years of age, inclusive.
  2. (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive, and a minimum weight of 50.0 kg.
  3. Continuous non-smoker for at least 3 months prior to screening and tests negative on urine cotinine confirmatory test.
  4. Female subjects of with male sexual partners must be using and willing to continue using medically acceptable for at least 1 month prior to screening (at least 3 months for oral and transdermal contraceptives) and for at least 1 month after the last study drug administration.
  5. Female subjects of non-childbearing potential
  6. Male subjects with female sexual partners of childbearing potential must be using and willing to continue using medically acceptable contraception from screening and for at least 1 month after the last study drug administration.
  7. Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
  8. Must provide written prior to the initiation of any protocol-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of any disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the study, such as evidence of gastrointestinal (GI), hepatic or renal disease that may affect absorption, distribution, metabolism, or excretion of the orally administered study drug.
  2. Recent history (within 4 weeks prior to screening) or current active infection associated with fever and/ or requiring antibiotic therapy.
  3. Presence of latent or chronic infection (eg, recurrent sinusitis, urinary tract infection, genital or ocular herpes).
  4. Any medical/surgical procedure or trauma within 4 weeks of the first study drug administration.
  5. Any within the previous 5 years, with the exception of superficial skin cancer treated with local therapy.
  6. Self-reported history of substance or alcohol dependence (excluding nicotine and caffeine) within the past 2 years, and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.
  7. Self-reported family history of substance abuse in an immediate family member (eg, parent, sibling or child).
  8. Positive urine drug screen.
  9. Positive breath alcohol test.
  10. History or presence of clinically significant abnormality as assessed by physical examination, medical history, ECGs, vital signs, or laboratory values, which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
  11. Evidence of clinically significant hepatic or renal impairment including (ALT) or aspartate aminotransferase (AST) >1.5 x (ULN), or >1 x ULN.
  12. Inability to fast for a minimum of 14 hours.
  13. Positive for hepatitis A, , , (HIV) or tuberculosis.
  14. Donation or loss of more than 500 mL whole blood within 30 days preceding entry into the Treatment phase.
  15. Plasma donation within 7 days prior to dosing of study drug.
  16. Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
  17. Female subjects who are currently pregnant (have a positive pregnancy test) or lactating or who are planning to become pregnant within 30 days of last study drug administration.
  18. History of severe allergic reaction (including anaphylaxis) to any substance, or previous status asthmaticus.
  19. History of allergy or to Flagyl®, ATI-1501, or other nitroimidazole derivatives.
  20. Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected to during the conduct of the study.
  21. Use of a prohibited medication, as specified in Section 4.4.1.
  22. Treatment with an drug within 30 days (if the elimination half-life is unknown) prior to first drug administration or is concurrently enrolled in any research judged not to be scientifically or medically compatible with this study.
  23. An employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  24. A subject who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
  25. A subject who has pending legal charges or is on probation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Fasting Condition

    Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet

    Drug: Metronidazole Tablet

  • Active comparator
    Fed Condition

    Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet

    Drug: Metronidazole Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Relative bioavailability

    Relative bioavailability of ATI-1501 compared to Flagyl® tablets under fasting and fed conditions

    Time frame: 48 hours

Secondary outcomes

  1. Palatability

    Palatability of ATI-1501

    Time frame: 4 hours

07

Study locations

1 site
  • INC Research Inc.
    Toronto, Ontario M5V2T3, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Dec 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 8, 2017
StartActual
Nov 6, 2017
Primary completionActual
Dec 13, 2017
CompletionActual
Dec 30, 2017
Last update
Jan 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03337126
Lead sponsor
Appili Therapeutics Inc.
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Nov 8, 2017
Start date
Nov 6, 2017
Primary completion
Dec 13, 2017
Completion
Dec 30, 2017
Last update
Jan 11, 2019

Study contacts

Michael McDonnell, MD
principal investigator · Syneos Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion